These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36318206)

  • 1. Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs.
    Gould P; Salam T; Kimberly L; Bateman-House A; Fernandez Lynch H
    JAMA Netw Open; 2022 Nov; 5(11):e2239766. PubMed ID: 36318206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center.
    Stout J; Smith C; Buckner J; Adjei AA; Wentworth M; Tilburt JC; Master Z
    PLoS One; 2021; 16(12):e0261478. PubMed ID: 34919568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Patient Expanded Access Requests: IRB Professionals' Experiences and Perspectives.
    Chapman CR; Shearston JA; Folkers KM; Redman BK; Caplan A; Bateman-House A
    AJOB Empir Bioeth; 2019; 10(2):88-99. PubMed ID: 30964737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expanded Access and Right To Try Requests: The Community Oncologist's Experience.
    Zettler ME; Jeune-Smith Y; Feinberg BA; Phillips EG; Gajra A
    JCO Oncol Pract; 2021 Nov; 17(11):e1719-e1727. PubMed ID: 33886355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A survey of pediatric hematologists/oncologists' perspectives on single patient Expanded Access and Right to Try.
    Chapman CR; Belli HM; Leach D; Shah LD; Bateman-House A
    Med Access Point Care; 2021; 5():23992026211005991. PubMed ID: 36204503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Access to Investigational Drugs: FDA Expanded Access Programs or "Right-to-Try" Legislation?
    Holbein ME; Berglund JP; Weatherwax K; Gerber DE; Adamo JE
    Clin Transl Sci; 2015 Oct; 8(5):526-32. PubMed ID: 25588691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National landscape assessment of academic medical center support for expanded access to investigational products.
    Gravelin M; Adamo JE; Ellison S; Segear E; Parrish AB; Deeter C; Hamill J; Rigan L; Mashour GA; Weatherwax KJ
    J Clin Transl Sci; 2023; 7(1):e4. PubMed ID: 36755539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try.
    Smith C; Stout J; Adjei AA; Buckner J; Wentworth M; Tilburt J; Master Z
    J Natl Cancer Inst; 2021 Jun; 113(6):735-741. PubMed ID: 32882030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient advocacy organizations' information for patients on pre-approval access to investigational treatments.
    Folkers KM; Leone S; Caplan A
    BMC Res Notes; 2019 Oct; 12(1):706. PubMed ID: 31661023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist.
    Fernandez Lynch H; Salam T; Gould P; Bateman-House A; Kimberly L
    JAMA Netw Open; 2023 Feb; 6(2):e230060. PubMed ID: 36800184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physician perspectives on compassionate use in pediatric oncology.
    Moerdler S; Zhang L; Gerasimov E; Zhu C; Wolinsky T; Roth M; Goodman N; Weiser DA
    Pediatr Blood Cancer; 2019 Mar; 66(3):e27545. PubMed ID: 30408307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taking AIM at serious illness: implementing an access to investigational medicines expanded access program.
    Joly MM; Edwards TL; Jerome RN; Mainor A; Bernard GR; Pulley JM
    Front Med (Lausanne); 2023; 10():1287449. PubMed ID: 37877021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oversight of Right-to-Try and Expanded Access Requests for Off-Trial Access to Investigational Drugs.
    Chapman CR; Eckman J; Bateman-House AS
    Ethics Hum Res; 2020 Jan; 42(1):2-13. PubMed ID: 31967412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try.
    Manley H; Sisk BA; Master Z; Scott CT
    J Law Biosci; 2022; 9(2):lsac031. PubMed ID: 36419857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-patient expanded access: A primer for pharmacists.
    Smith AJF; Redic KA
    Am J Health Syst Pharm; 2022 Nov; 79(23):2118-2127. PubMed ID: 36056791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What do patients with unmet medical needs want? A qualitative study of patients' views and experiences with expanded access to unapproved, investigational treatments in the Netherlands.
    Bunnik EM; Aarts N
    BMC Med Ethics; 2019 Nov; 20(1):80. PubMed ID: 31706313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.